A carregar...
FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma is the most common lymphoid malignancy, as it accounts for approximately one third of all patient cases of non-Hodgkin’s lymphoma. Patients with diffuse large B-cell lymphoma have markedly different treatment outcomes, suggesting a need for reliable prognostic factors a...
Na minha lista:
| Publicado no: | J Hematop |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4415532/ https://ncbi.nlm.nih.gov/pubmed/25937841 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|